Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024

Published on April 13, 2024 at 12:18 pm by Fahad Saleem in Hedge Funds, News

In this article, we will take a detailed look at Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024. For a quick overview of such stocks, read our article Jim Cramer’s 5 Favorite Healthcare Stock Picks in 2024.

Jim Cramer kicked off 2024 with a positive note for the healthcare sector, saying in a program in January that the biopharmaceutical sector had apparently “rediscovered its urge to merge.”

Rediscovering the “Urge to Merge”

Cramer said M&A activity has been a big driver for the industry because when major companies lose patent protections for their drugs, they buy small biotechnology companies which also need bigger companies for distribution, sales and marketing infrastructure. Cramer said because of these complementary dynamics, everybody wins, and “you win if you own them.”

The Tide is Turning for Healthcare Companies According to Cramer

However, Cramer said that the M&A activity in the healthcare industry came to a halt amid FTC’s brutal stance against mergers, headed by FTC chairperson Lina Khan, who, according to Cramer, thinks all kinds of M&A activity is anticompetitive. But the environment is now changing according to Cramer. He highlighted the FTC’s failure to block’s Amgen’s $27.8 billion deal to buy Horizon Therapeutics. This development was “transformative” for the industry, Cramer said. Another deal that brought optimism in the industry was Pfizer’s buyout of Seagen for $43 billion. Cramer said that perhaps the “anger” against corporate America is subsiding too, which is why healthcare companies are deciding to give M&A “another shot.” Cramer mentioned a host of deal announcements from major companies like AbbVie, Roche and AstraZeneca.

Jim Cramer is also highly bullish on weight loss and diabetes drug companies and regularly talks about how GLP-1 drugs are bringing new opportunities for investors. In our recent article we also talked about how the rise of weight loss drugs and new growth catalysts are causing corporate insiders to pile into several healthcare stocks.

Jim Cramer is Bullish on Small-Cap Healthcare Stocks in 2024

Jim Cramer said in one of his latest programs on CNBC that he continues to believe that small-cap stocks would rebound in 2024. However, he thinks that the broader small-cap stock indices are underperforming the S&P 500 even during the 2024 stock rally, and there are many reasons for that. Without going into those reasons, Cramer discussed some of his top small-cap healthcare picks in detail. Cramer said that there are about 400 healthcare stocks in the small cap-focused Russell 2000. The CNBC host said most of these stocks are biotech names and “most of them are bad.” Jim Cramer said he ran a screen for these stocks with an intention to choose small-cap healthcare stocks with positive earnings and “reasonable valuations” and ended up getting just 48 stocks as a result. From these 48 companies, Cramer focused on five small-cap healthcare stocks which we discuss in detail in our article.

Cramer’s Favorite Healthcare Stocks for 2024

For this article we watched latest programs of Jim Cramer and picked his top healthcare stock recommendations. We have sorted the list based on hedge fund sentiment, courtesy of Insider Monkey’s database of 933 hedge fund and their stock holdings. Some top names in the list include Eli Lilly And Co (NYSE:LLY), UnitedHealth Group Inc (NYSE:UNH) and Abbott Laboratories (NYSE:ABT). Hedge funds’ top 10 consensus stock picks outperformed the S&P 500 Index by more than 140 percentage points over the last 10 years (see the details here).

10. Addus Homecare Corporation (NASDAQ:ADUS)

Number of Hedge Fund Investors: 17

Jim Cramer thinks one of the most “investable” themes in the healthcare industry is moving away from providing care in hospitals to “other, lower cost settings” like outpatient centers of patients’ homes. Addus Homecare Corporation (NASDAQ:ADUS) does exactly that since it offers in-home medical care and in-home assistance, in addition to hospice care services at home. Cramer said that currently Addus Homecare Corporation (NASDAQ:ADUS) makes most of its revenue from Illinois, New York and New Mexico but it’s expanding to new areas via acquisitions. Cramer highlighted Addus Homecare Corporation’s (NASDAQ:ADUS) $106 million acquisition of Tennessee Quality Care last year. Cramer also said Addus Homecare Corporation (NASDAQ:ADUS) posted strong “top and bottom line beat” in its latest earnings report and the management sounded optimistic and upbeat about 2024.

9. Integer Holdings Corp (NYSE:ITGR)

Number of Hedge Fund Investors: 18

Integer Holdings Corp (NYSE:ITGR) ranks ninth in our list of the best healthcare stocks to buy according to Jim Cramer in 2024. Integer Holdings Corp (NYSE:ITGR) is a medical device outsource (MDO) manufacturer. Cramer said that major healthcare companies like Medtronic, Abbot Laboratories and Boston Scientific go to companies like Integer Holdings Corp (NYSE:ITGR) to actually “design their stuff.” Cramer said that Integer Holdings Corp (NYSE:ITGR) benefits from high healthcare utilization rates since it’s taking “years” for people to get their non-urgent medical procedures due to the pandemic effects. Cramer also said that Integer keeps its portfolio “fresh” by making acquisitions.

In addition to ITGR, Cramer is also recommending Eli Lilly And Co (NYSE:LLY), UnitedHealth Group Inc (NYSE:UNH) and Abbott Laboratories (NYSE:ABT).

8. Owens & Minor Inc (NYSE:OMI)

Number of Hedge Fund Investors: 20

Healthcare logistics company Owens & Minor Inc (NYSE:OMI) is one of the best small-cap healthcare stocks to buy in 2024 according to Jim Cramer. He said Owens & Minor Inc (NYSE:OMI) came on his radar during the pandemic days because Owens & Minor Inc (NYSE:OMI) made Personal Protective Equipment (PPE). Cramer said that Owens & Minor Inc (NYSE:OMI) made good use of the money it made during the pandemic as it initiated “a pair of” acquisitions in the home health space. As a result, Owens & Minor Inc’s (NYSE:OMI) “patient direct segment” has seen a lot of growth while its PPE segment declined. Cramer said Owens & Minor Inc (NYSE:OMI) conducted its investor day event in December where it outlined strong earnings growth expectations which impressed Cramer.

In February, during an earnings call, the company talked about guidance and performance of its Patient Direct segment:

“As a result of this significant cash flow, we reduced total debt by $49 million for the fourth quarter and by $403 million for the full year, bringing the balance to $2.1 billion at year-end. In addition, we reduced net debt by $76 million in the fourth quarter and by $577 million for the full year, bringing the balance to $1.9 billion. Net book leverage was 3.5 times at the end of the fourth quarter. Now, let’s look at our full year 2024 guidance. Consistent with what we discussed on the third quarter call and at Investor Day, we expect net revenue to be in the range of $10.5 billion to $10.9 billion, adjusted EBITDA to be in the range of $550 million to $590 million, and adjusted EPS to be in the range of $1.40 to $1.70. Also, as previously discussed, we expect the earnings trajectory to follow our normal seasonal pattern throughout the year.

To help some of you with your models, we’d expect that seasonality to lead to a roughly one-thirds/two-thirds split across the first and second half of the year from an earnings perspective and we’d expect to deliver improvement in each sequential quarter. Looking ahead, we remain committed to delivering the outlook for both segments, having outpaced market growth in our Patient Direct segment and delivered year-over-year profit improvement in Products and Healthcare Services. As we enter 2024, we’re excited to sustain this momentum and to continue on the initial phase of our five year strategy and investment plan, laying the groundwork for continued future success.”

Read the full earnings call transcript here.

7. Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)

Number of Hedge Fund Investors: 26

Biotechnology company Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) is one of the best small-cap healthcare stock picks of Cramer this year. Cramer said Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) is more of an “investor” than an “inventor” since it buys promising early stage drugs and then brings them into the market. Cramer said Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) recently launched its third drug.

In January 2024, Cramer had said that since he didn’t know anything about Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) he cannot comment on it. However, in his latest program, Cramer said the stock has gone “nowhere” since he told his viewers to “ignore” it which means he hasn’t “missed anything” and it’s still a good time to buy the stock.

6. Progyny Inc (NASDAQ:PGNY)

Number of Hedge Fund Investors: 28

Fertility benefits management company Progyny Inc (NASDAQ:PGNY) is one of the healthcare stock picks of Jim Cramer in 2024. Cramer recently said he’s been “loosely following” the company since it went public. Cramer said that businesses partner with Progyny Inc (NASDAQ:PGNY) to offer family building benefits to their employees. Cramer said Progyny Inc (NASDAQ:PGNY) has been a “rapid grower” but the stock does not reflect this. He thinks the stock has been “stuck” since 2022 and recently it saw a significant pullback amid a guidance that was “confusing” and some “timing issues.” However, Cramer likes Progyny Inc’s (NASDAQ:PGNY) revenue growth (18% to 21%) and earnings growth (10% to 14%). Cramer reiterated that the stock is “enticing.”

In addition to PGNY, Cramer also likes Eli Lilly And Co (NYSE:LLY), UnitedHealth Group Inc (NYSE:UNH) and Abbott Laboratories (NYSE:ABT).

Polen Global SMID Company Growth Strategy made the following comment about Progyny, Inc. (NASDAQ:PGNY) in its Q3 2023 investor letter:

“We bought a new position in Progyny, Inc. (NASDAQ:PGNY), a company owned in our U.S. strategies for some time. They are a leading provider of fertility benefit solutions, and through their differentiated approach, their clients can pursue the most effective treatment and achieve optimal outcomes. We believe the company has only a mid-single digit share of its potential total addressable market and is the most dominant player within the fast-growing managed care category. They are already profitable, earn high returns on incremental capital, and have plenty of runway to grow top-line growth as they continue to win new clients and add new services.”

Click to continue reading and see Jim Cramer’s 5 Favorite Healthcare Stock Picks in 2024.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on May 1, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

Published on May 2, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up